Lessons from next generation influenza vaccines for inflammatory disease therapies
Lessons can be learned for treating inflammatory diseases such as rheumatoid arthritis (RA) from next generation approaches for development of universal influenza vaccines. Immunomodulation of inflammatory diseases, rather than ablation of cytokine or cellular responses, can address the root cause o...
Gespeichert in:
| Veröffentlicht in: | International immunopharmacology 2019-09, Vol.74, p.105729-105729, Article 105729 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 105729 |
|---|---|
| container_issue | |
| container_start_page | 105729 |
| container_title | International immunopharmacology |
| container_volume | 74 |
| creator | Zimmerman, Daniel H. Carambula, Roy E. Ciemielewski, Jason Rosenthal, Ken S. |
| description | Lessons can be learned for treating inflammatory diseases such as rheumatoid arthritis (RA) from next generation approaches for development of universal influenza vaccines. Immunomodulation of inflammatory diseases, rather than ablation of cytokine or cellular responses, can address the root cause of the disease and provide potential cure. Like influenza, there are different antigenic ‘strains’ and inflammatory T cell responses, Th1 or Th17, that drive each person's disease. As such, next generation vaccine-like antigen specific therapies for inflammatory diseases can be developed but will need to be customized to the patient depending upon the antigen and T cell response that is driving the disease.
•T cell immunogens are Next Generation influenza vaccines.•Antigen specific rheumatoid arthritis (RA) therapy will target T cells.•Immunomodulation rather than ablation may provide cure of RA.•Triggers and immune responses driving RA are individualistic.•Antigen specific therapy for rheumatoid arthritis can be personalized. |
| doi_str_mv | 10.1016/j.intimp.2019.105729 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6719783</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567576919311646</els_id><sourcerecordid>2296645745</sourcerecordid><originalsourceid>FETCH-LOGICAL-c458t-59b133563e158c4326f7e7c6af31a80e18747fdc3f72d10efe7df98c92e1dbc3</originalsourceid><addsrcrecordid>eNp9UdtKAzEUDKLYevkDkQWftyabTbL7IkjxBgVBfA9p9sSmdJOapMX69Ubr9cWnhMnMnMkZhE4IHhFM-Pl8ZF2y_XJUYdJmiImq3UFD0oimJAKz3XxnXJRM8HaADmKcY5zxmuyjASVVgzHjQ_QwgRi9i4UJvi8cvKTiCRwElax3hXVmsQL3qoq10to6yDwfPmDV9yr5sCk6G0FFKNIsq5YW4hHaM2oR4fjzPESP11eP49tycn9zN76clLpmTSpZOyWUMk6BsEbXtOJGgNBcGUpUgyF_pBam09SIqiMYDIjOtI1uKyDdVNNDdLG1Xa6mPXQaXApqIZfB9ipspFdW_n1xdiaf_FpyQVrR0Gxw9mkQ_PMKYpJzvwouR5ZV1XJeM1GzzKq3LB18jAHM9wSC5XsRci63Rcj3IuS2iCw7_Z3uW_S1-Z_4kFe0thBk1Bachs4G0El23v4_4Q1JUJ5m</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2296645745</pqid></control><display><type>article</type><title>Lessons from next generation influenza vaccines for inflammatory disease therapies</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Zimmerman, Daniel H. ; Carambula, Roy E. ; Ciemielewski, Jason ; Rosenthal, Ken S.</creator><creatorcontrib>Zimmerman, Daniel H. ; Carambula, Roy E. ; Ciemielewski, Jason ; Rosenthal, Ken S.</creatorcontrib><description>Lessons can be learned for treating inflammatory diseases such as rheumatoid arthritis (RA) from next generation approaches for development of universal influenza vaccines. Immunomodulation of inflammatory diseases, rather than ablation of cytokine or cellular responses, can address the root cause of the disease and provide potential cure. Like influenza, there are different antigenic ‘strains’ and inflammatory T cell responses, Th1 or Th17, that drive each person's disease. As such, next generation vaccine-like antigen specific therapies for inflammatory diseases can be developed but will need to be customized to the patient depending upon the antigen and T cell response that is driving the disease.
•T cell immunogens are Next Generation influenza vaccines.•Antigen specific rheumatoid arthritis (RA) therapy will target T cells.•Immunomodulation rather than ablation may provide cure of RA.•Triggers and immune responses driving RA are individualistic.•Antigen specific therapy for rheumatoid arthritis can be personalized.</description><identifier>ISSN: 1567-5769</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2019.105729</identifier><identifier>PMID: 31280056</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Ablation ; Antigens ; Antigens, Viral - immunology ; Arthritis ; Disease ; Helper cells ; Humans ; Immunomodulation ; Immunotherapy - methods ; Inflammation ; Inflammatory diseases ; Influenza ; Influenza Vaccines - immunology ; Influenza, Human - immunology ; Lymphocytes ; Lymphocytes T ; Orthomyxoviridae - physiology ; Precision Medicine ; Rheumatoid arthritis ; T cells ; Th1 Cells - immunology ; Th1-Th2 Balance ; Th2 Cells - immunology ; Vaccine therapy ; Vaccines</subject><ispartof>International immunopharmacology, 2019-09, Vol.74, p.105729-105729, Article 105729</ispartof><rights>2019 Elsevier B.V.</rights><rights>Copyright © 2019 Elsevier B.V. All rights reserved.</rights><rights>Copyright Elsevier BV Sep 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c458t-59b133563e158c4326f7e7c6af31a80e18747fdc3f72d10efe7df98c92e1dbc3</citedby><cites>FETCH-LOGICAL-c458t-59b133563e158c4326f7e7c6af31a80e18747fdc3f72d10efe7df98c92e1dbc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1567576919311646$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31280056$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zimmerman, Daniel H.</creatorcontrib><creatorcontrib>Carambula, Roy E.</creatorcontrib><creatorcontrib>Ciemielewski, Jason</creatorcontrib><creatorcontrib>Rosenthal, Ken S.</creatorcontrib><title>Lessons from next generation influenza vaccines for inflammatory disease therapies</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>Lessons can be learned for treating inflammatory diseases such as rheumatoid arthritis (RA) from next generation approaches for development of universal influenza vaccines. Immunomodulation of inflammatory diseases, rather than ablation of cytokine or cellular responses, can address the root cause of the disease and provide potential cure. Like influenza, there are different antigenic ‘strains’ and inflammatory T cell responses, Th1 or Th17, that drive each person's disease. As such, next generation vaccine-like antigen specific therapies for inflammatory diseases can be developed but will need to be customized to the patient depending upon the antigen and T cell response that is driving the disease.
•T cell immunogens are Next Generation influenza vaccines.•Antigen specific rheumatoid arthritis (RA) therapy will target T cells.•Immunomodulation rather than ablation may provide cure of RA.•Triggers and immune responses driving RA are individualistic.•Antigen specific therapy for rheumatoid arthritis can be personalized.</description><subject>Ablation</subject><subject>Antigens</subject><subject>Antigens, Viral - immunology</subject><subject>Arthritis</subject><subject>Disease</subject><subject>Helper cells</subject><subject>Humans</subject><subject>Immunomodulation</subject><subject>Immunotherapy - methods</subject><subject>Inflammation</subject><subject>Inflammatory diseases</subject><subject>Influenza</subject><subject>Influenza Vaccines - immunology</subject><subject>Influenza, Human - immunology</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Orthomyxoviridae - physiology</subject><subject>Precision Medicine</subject><subject>Rheumatoid arthritis</subject><subject>T cells</subject><subject>Th1 Cells - immunology</subject><subject>Th1-Th2 Balance</subject><subject>Th2 Cells - immunology</subject><subject>Vaccine therapy</subject><subject>Vaccines</subject><issn>1567-5769</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UdtKAzEUDKLYevkDkQWftyabTbL7IkjxBgVBfA9p9sSmdJOapMX69Ubr9cWnhMnMnMkZhE4IHhFM-Pl8ZF2y_XJUYdJmiImq3UFD0oimJAKz3XxnXJRM8HaADmKcY5zxmuyjASVVgzHjQ_QwgRi9i4UJvi8cvKTiCRwElax3hXVmsQL3qoq10to6yDwfPmDV9yr5sCk6G0FFKNIsq5YW4hHaM2oR4fjzPESP11eP49tycn9zN76clLpmTSpZOyWUMk6BsEbXtOJGgNBcGUpUgyF_pBam09SIqiMYDIjOtI1uKyDdVNNDdLG1Xa6mPXQaXApqIZfB9ipspFdW_n1xdiaf_FpyQVrR0Gxw9mkQ_PMKYpJzvwouR5ZV1XJeM1GzzKq3LB18jAHM9wSC5XsRci63Rcj3IuS2iCw7_Z3uW_S1-Z_4kFe0thBk1Bachs4G0El23v4_4Q1JUJ5m</recordid><startdate>20190901</startdate><enddate>20190901</enddate><creator>Zimmerman, Daniel H.</creator><creator>Carambula, Roy E.</creator><creator>Ciemielewski, Jason</creator><creator>Rosenthal, Ken S.</creator><general>Elsevier B.V</general><general>Elsevier BV</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20190901</creationdate><title>Lessons from next generation influenza vaccines for inflammatory disease therapies</title><author>Zimmerman, Daniel H. ; Carambula, Roy E. ; Ciemielewski, Jason ; Rosenthal, Ken S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c458t-59b133563e158c4326f7e7c6af31a80e18747fdc3f72d10efe7df98c92e1dbc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Ablation</topic><topic>Antigens</topic><topic>Antigens, Viral - immunology</topic><topic>Arthritis</topic><topic>Disease</topic><topic>Helper cells</topic><topic>Humans</topic><topic>Immunomodulation</topic><topic>Immunotherapy - methods</topic><topic>Inflammation</topic><topic>Inflammatory diseases</topic><topic>Influenza</topic><topic>Influenza Vaccines - immunology</topic><topic>Influenza, Human - immunology</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Orthomyxoviridae - physiology</topic><topic>Precision Medicine</topic><topic>Rheumatoid arthritis</topic><topic>T cells</topic><topic>Th1 Cells - immunology</topic><topic>Th1-Th2 Balance</topic><topic>Th2 Cells - immunology</topic><topic>Vaccine therapy</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zimmerman, Daniel H.</creatorcontrib><creatorcontrib>Carambula, Roy E.</creatorcontrib><creatorcontrib>Ciemielewski, Jason</creatorcontrib><creatorcontrib>Rosenthal, Ken S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zimmerman, Daniel H.</au><au>Carambula, Roy E.</au><au>Ciemielewski, Jason</au><au>Rosenthal, Ken S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lessons from next generation influenza vaccines for inflammatory disease therapies</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2019-09-01</date><risdate>2019</risdate><volume>74</volume><spage>105729</spage><epage>105729</epage><pages>105729-105729</pages><artnum>105729</artnum><issn>1567-5769</issn><eissn>1878-1705</eissn><abstract>Lessons can be learned for treating inflammatory diseases such as rheumatoid arthritis (RA) from next generation approaches for development of universal influenza vaccines. Immunomodulation of inflammatory diseases, rather than ablation of cytokine or cellular responses, can address the root cause of the disease and provide potential cure. Like influenza, there are different antigenic ‘strains’ and inflammatory T cell responses, Th1 or Th17, that drive each person's disease. As such, next generation vaccine-like antigen specific therapies for inflammatory diseases can be developed but will need to be customized to the patient depending upon the antigen and T cell response that is driving the disease.
•T cell immunogens are Next Generation influenza vaccines.•Antigen specific rheumatoid arthritis (RA) therapy will target T cells.•Immunomodulation rather than ablation may provide cure of RA.•Triggers and immune responses driving RA are individualistic.•Antigen specific therapy for rheumatoid arthritis can be personalized.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>31280056</pmid><doi>10.1016/j.intimp.2019.105729</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1567-5769 |
| ispartof | International immunopharmacology, 2019-09, Vol.74, p.105729-105729, Article 105729 |
| issn | 1567-5769 1878-1705 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6719783 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Ablation Antigens Antigens, Viral - immunology Arthritis Disease Helper cells Humans Immunomodulation Immunotherapy - methods Inflammation Inflammatory diseases Influenza Influenza Vaccines - immunology Influenza, Human - immunology Lymphocytes Lymphocytes T Orthomyxoviridae - physiology Precision Medicine Rheumatoid arthritis T cells Th1 Cells - immunology Th1-Th2 Balance Th2 Cells - immunology Vaccine therapy Vaccines |
| title | Lessons from next generation influenza vaccines for inflammatory disease therapies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T16%3A01%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lessons%20from%20next%20generation%20influenza%20vaccines%20for%20inflammatory%20disease%20therapies&rft.jtitle=International%20immunopharmacology&rft.au=Zimmerman,%20Daniel%20H.&rft.date=2019-09-01&rft.volume=74&rft.spage=105729&rft.epage=105729&rft.pages=105729-105729&rft.artnum=105729&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2019.105729&rft_dat=%3Cproquest_pubme%3E2296645745%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2296645745&rft_id=info:pmid/31280056&rft_els_id=S1567576919311646&rfr_iscdi=true |